Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
7 - The newly diagnosed patient with essential thrombocythemia
Published online by Cambridge University Press: 05 March 2016
Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Managing Myeloproliferative NeoplasmsA Case-Based Approach, pp. 56 - 63Publisher: Cambridge University PressPrint publication year: 2016
References
Swerdlow, S.H., Campo, E., Harris, N.L., et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon, 2008.Google Scholar
Barbui, T., Thiele, J., Passamonti, F., Rumi E, ., Boveri, E., Ruggeri, M. et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011;29:3179–84.CrossRefGoogle ScholarPubMed
Finazzi, G. How to manage essential thrombocythemia. Leukemia 2012;26:875–82.CrossRefGoogle ScholarPubMed
Harrison, C.N., Campbell, P.J., Buck, G., Wheatley, K., East, C.L., Bareford, D. et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia N Engl J Med 2005;353:33–45.CrossRefGoogle ScholarPubMed
Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F. et al. Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial. N Engl J Med 1995;332:1132–6.CrossRefGoogle Scholar
Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Rumi, E., Ruggeri, M. et al. Incidence and risk factors for bleeding in 1,104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008-WHO-criteria. Leukemia 2012;26:716–19.CrossRefGoogle Scholar
Ruggeri, M., Finazzi, G., Tosetto, A., Riva, S., Rodeghiero, F., Barbui, T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol 1998;103:772–7.CrossRefGoogle ScholarPubMed
Alvarez-Larran, A., Cervantes, F., Pereira, A., Arellano-Rodrigo, E., Pérez-Andreu, V., Hernández-Boluda, J.C. et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010;116:1205–10.CrossRefGoogle ScholarPubMed
Barbui, T., Carobbio, A., Rambaldi, A., Finazzi, G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 2009;114:759–63.CrossRefGoogle ScholarPubMed
Barbui, T., Finazzi, G., Falanga, A. Myeloproliferative neoplasms and thrombosis. Blood 2013;122: 2176–84.CrossRefGoogle ScholarPubMed
Lussana, F., Caberlon, S., Pagani, C., Kamphuisen, P.W., Büller, H.R., Cattaneo, M. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythemia or idiopathic myelofibrosis: a systematic review. Thromb Res 2009;124:409–17.CrossRefGoogle ScholarPubMed
Klampfl, T., Gisslinger, H., Harutyunyan, A.S., Nivarthi, H., Rumi, E., Milosevic, J.D. et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369:2379–90.CrossRefGoogle ScholarPubMed
Rumi, E., Pietra, D., Ferretti, V., Klampfl, T., Harutyunyan, A.S., Milosevic, J.D. et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2014;123:1544–51.CrossRefGoogle ScholarPubMed
Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M. et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761–70.CrossRefGoogle ScholarPubMed
Barbui, T., Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Rumi, E. et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012;120:5128–33.CrossRefGoogle ScholarPubMed
Bjorkholm, J., Derolf, A.R., Ekstrand, C., Kristinsson, S. Y., Ekstrand, C., Goldin, L.R. et al. Clinical risk for AML/MDS transformation in Philadelphia negative chronic myeloproliferative neoplasms. A population-based nested case-control study in Sweden. J Clin Oncol 2011;29:2410–15.Google Scholar
Gisslinger, H., Gotic, M., Holowiecki, J., Penka, M., Thiele, J., Kvasnicka, H.M. et al. Anagrelide compared to hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood 2013;121:1720–8.CrossRefGoogle ScholarPubMed
Quintas-Cardama, A., Kantarjian, H., Manshouri, T., Luthra, R., Estrov, Z., Pierce, S. et al. Pegylated interferon alpha-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009:27:5418–24.CrossRefGoogle ScholarPubMed
Verger, E., Cassinat, B., Dosquet, C., Andreoli, A., Schlageter, M.H., Chomienne, C. et al. Clinical and molecular response to interferon alpha therapy in essential thrombocythemia patients with CALR mutations. Proceedings of the 19th Congress of the European Hematology Association, Milan, June 12–15, 2014 (abstract 4658).Google Scholar
Verstovsek, S., Passamonti, F., Rambaldi, A., Barosi, G., Rosen, P.J., Levy, R. et al. Durable responses with the JAK1/ JAK2 inhibitor, INCB018424, in patients with polycythemia vera (PV) and essential thrombocythemia (ET) refractory or intolerant to hydroxyurea (HU). Blood 2010;116 (abstract 313).CrossRefGoogle Scholar
Barosi, G., Mesa, R., Finazzi, G., Harrison, C., Kiladijan, J.J., Lengfelder, E. et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 2013;121:4778–81.CrossRefGoogle ScholarPubMed